Orforglipron (Foundayo): Oral GLP-1 Pill Evidence, Label and Limits
Evidence-aware guide to orforglipron, sold as Foundayo, including FDA approval, oral GLP-1 mechanism, trial results, dose schedule and safety limits.
Orforglipron matters to PeptideStat readers for a slightly odd reason: it is not a peptide. It is a small-molecule GLP-1 receptor agonist taken by mouth and sold as Foundayo. That makes it a direct comparison point for injectable GLP-1 peptides and for oral semaglutide, the peptide-based GLP-1 tablet discussed in the oral peptides guide.
The FDA announced Foundayo approval on April 1, 2026 for use with reduced- calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight and at least one weight-related comorbidity. That puts it in the same weight-management conversation as Wegovy, Zepbound, and the broader FDA-approved GLP-1 list.
The honest angle is not that a pill is automatically better than an injection. The evidence says orforglipron can produce clinically meaningful weight loss and glucose effects in studied populations, with GLP-1 class adverse effects and product-specific warnings. It is an approved drug, not a research peptide protocol, and the label, clinician oversight and contraindications matter.
This guide is educational and not medical advice. GLP-1 medicines are used in people with different diabetes status, kidney function, gastrointestinal risk, pregnancy considerations, drug interactions and surgical plans. Personal decisions belong with a licensed clinician.
Orforglipron At A Glance
| Question | Evidence-aware answer |
|---|---|
| Brand name | Foundayo |
| Drug type | Oral, small-molecule, nonpeptide GLP-1 receptor agonist |
| FDA status | Approved April 1, 2026 for chronic weight management in the labeled adult population |
| Dosing form | Once-daily oral tablet |
| Main evidence base | Phase 3 obesity and type 2 diabetes trials, plus pharmacokinetic and pooled safety analyses |
| Key distinction | Unlike oral semaglutide, it is not a peptide tablet that depends on SNAC-enabled peptide absorption |
| Main adverse-event theme | Gastrointestinal effects such as nausea, constipation, diarrhea and vomiting |
Why A Nonpeptide GLP-1 Belongs In A Peptide Library
GLP-1 itself is a peptide hormone, and many major GLP-1 drugs are peptide or peptide-like injectables. Semaglutide, liraglutide, dulaglutide and exenatide all sit in that wider peptide-drug lineage. Orforglipron uses the same receptor target but arrives by a different chemistry route.
That chemistry matters. Most systemic peptides do not survive ordinary oral delivery well. Oral semaglutide works because it is a specific tablet formulation with the absorption enhancer SNAC and strict administration rules. Orforglipron is designed as a small molecule, so the oral-delivery problem is different. A food-effect study found lower exposure under fed conditions, but the authors concluded the observed pharmacokinetic differences were unlikely to create clinically meaningful efficacy differences.
That does not mean all oral GLP-1 pills are interchangeable. It means readers should separate three categories:
| Category | Example | Why it matters |
|---|---|---|
| Peptide GLP-1 injection | Semaglutide injection, liraglutide, dulaglutide | Large regulated evidence bases, injection route and brand-specific labels. |
| Peptide GLP-1 oral tablet | Oral semaglutide | Uses formulation-specific absorption logic and administration rules. |
| Nonpeptide GLP-1 oral tablet | Orforglipron | Small-molecule route with different absorption and dosing constraints. |
For receptor background, read what GLP-1 is and the GLP-1 receptor agonist guide. For brand comparisons, use the GLP-1 drugs list.
What The FDA Approval Covers
The FDA announcement describes Foundayo as a once-daily oral GLP-1 receptor agonist tablet. It states that Foundayo is approved for chronic weight management in adults with obesity, or overweight adults with at least one weight-related comorbidity, when used with reduced-calorie diet and increased physical activity.
The FDA page also gives a dose-escalation outline. The starting dose is 0.8 mg once daily, increased to 2.5 mg after at least 30 days and then to 5.5 mg after another 30 days. Depending on response and tolerability, the dose may be increased further to 9 mg, 14.5 mg or 17.2 mg after at least 30 days at each level.
That is label context, not personal dose advice. It also differs from older trial-dose language. PeptideStat's GLP-1 dosage guide explains why weight-management labels use slow escalation to balance exposure and tolerability.
What The Obesity Trial Found
The main obesity evidence comes from ATTAIN-1, a multinational phase 3 trial published in the New England Journal of Medicine. Adults with obesity and without diabetes received once-daily orforglipron 6 mg, 12 mg or 36 mg, or placebo, for 72 weeks alongside diet and physical activity.
The treatment-regimen estimand showed greater mean body-weight reduction with orforglipron than placebo:
| Group | Mean body-weight change at week 72 |
|---|---|
| Placebo | -2.1% |
| Orforglipron 6 mg | -7.5% |
| Orforglipron 12 mg | -8.4% |
| Orforglipron 36 mg | -11.2% |
In the 36 mg group, 54.6% of participants had at least 10% weight reduction, 36.0% had at least 15% weight reduction and 18.4% had at least 20% weight reduction. The placebo group rates were 12.9%, 5.9% and 2.8%, respectively.
Those are meaningful trial results, but they should not be inflated into a "best GLP-1" verdict. Cross-trial comparisons can mislead because semaglutide, tirzepatide and orforglipron trials differ in duration, population, estimand, dose, adherence and discontinuation. Use the Zepbound vs Wegovy and semaglutide vs tirzepatide guides for approved injectable comparisons.
Type 2 Diabetes Evidence And Oral Semaglutide Comparison
ACHIEVE-3 compared once-daily oral orforglipron with oral semaglutide in adults with type 2 diabetes inadequately controlled on metformin. The trial tested orforglipron 12 mg and 36 mg against oral semaglutide 7 mg and 14 mg.
The study met its primary noninferiority objective and reported greater HbA1c reductions for orforglipron doses than the oral semaglutide comparator doses. That is a clinically important result, but the tolerability comparison was not one-sided. Gastrointestinal events, adverse-event discontinuations and pulse rate increases were higher in the orforglipron groups than the oral semaglutide groups in the abstract.
| Comparison point | What ACHIEVE-3 indicates |
|---|---|
| Glucose lowering | Orforglipron met noninferiority and showed greater HbA1c reduction than oral semaglutide in this study. |
| Route | Both were once-daily oral GLP-1 options, but orforglipron was designed without food or water restrictions. |
| Tolerability | GI events and discontinuations were higher with orforglipron in the trial abstract. |
| Interpretation | Strong diabetes evidence, but not proof that one oral GLP-1 suits every patient better. |
For the broader class, see GLP-1 treatment guide and GLP-1 vs SGLT2 inhibitors.
Safety Warnings To Read Before The Convenience Story
The FDA announcement lists common side effects including nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, fatigue, burping, gastroesophageal reflux disease, gas and hair loss. It also names warnings and precautions for pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, hypoglycemia, hypersensitivity, diabetic retinopathy in people with type 2 diabetes, acute gallbladder disease and pulmonary aspiration during general anesthesia or deep sedation.
The labeling also includes a boxed warning for thyroid C-cell tumors and says Foundayo should not be used in people with a personal or family history of medullary thyroid cancer or in people with Multiple Endocrine Neoplasia syndrome type 2.
That means "pill form" should not be confused with low-risk supplement logic. Orforglipron is still a systemic GLP-1 drug. People with persistent vomiting, severe abdominal pain, dehydration risk, gallbladder symptoms, diabetes medication combinations, upcoming procedures or relevant cancer history need clinician-specific guidance. For class context, read GLP-1 side effects and GLP-1 before surgery.
Liver Safety And The Pfizer Oral GLP-1 Lesson
Oral GLP-1 development has had setbacks. Pfizer discontinued danuglipron development after liver-safety concerns, which made hepatic safety a sharper question for every oral small-molecule GLP-1 program.
For orforglipron, a pooled hepatic safety analysis across seven phase 3 trials included 11,220 participants. The abstract reports that orforglipron was not associated with drug-induced liver injury and that there were no cases consistent with Hy's Law for orforglipron. That does not remove all clinical monitoring questions, but it directly addresses one of the biggest concerns in the oral small-molecule GLP-1 category.
Claims about buying orforglipron outside a regulated pharmacy should be treated as a separate risk. A prescription tablet with an FDA-reviewed manufacturing process is not equivalent to an online "research chemical" pill or compounded lookalike.
Bottom Line
Orforglipron, sold as Foundayo, is a major GLP-1 development because it brings an approved once-daily small-molecule tablet into chronic weight management. It is not a peptide, but it directly affects how patients and clinicians think about oral versus injectable GLP-1 options.
The evidence supports a real role in the labeled population, with meaningful weight loss in ATTAIN-1 and diabetes evidence in ACHIEVE-3. The limits are just as practical: it remains a systemic GLP-1 drug with GI adverse effects, boxed warning language, pancreatitis and gallbladder warnings, dehydration-related kidney cautions, procedure considerations and brand-specific dosing. The best question is not "pill or injection?" It is which regulated product, for which patient, under which label, with which risks monitored.
References
FDA. FDA Approves First New Molecular Entity Under National Priority Voucher Program. April 1, 2026.
Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025.
Frias JP, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3). Lancet. 2026.
Pratt EJ, et al. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024.
Chakladar S, et al. Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials. Diabetes Obes Metab. 2026.
Wharton S, et al. Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc Diabetol. 2025.
Zhou J, et al. The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol. 2025.